Cardiac Imaging News

A new contrast agent can be applied for labeling cardiomyocytes for imaging…

A recent study, published in the current issue of Cell Transplantation, showed that using the , FDA-approved, contrast agent Indocyanine Green (ICG) for labeling human, embryonic stem cell-derived, cardiomyocytes (hESC-CMs) would significantly enhance efforts carried out to optically track stem cells after transplantation into cardiac tissues. The study was performed by the Departments of Radiology at the University of California and the Technical University of Munich. Dr. Sophie E. Boddington of the UCSF Department of Radiology, said "We found that hESC-CMs labeled with ICG show a significant fluorescence up to 48 hours and can be visualized with optical imaging," she added "Once more, the labeling procedure did not impair the viability or functional integrity of the cells." Based on the study, developing an efficient stem cell delivery technique was always a challenge. A lot of stem cells when aimed at myocardial regeneration were "washed away" into non-cardiac tissues or even die soon. A 10% survival rate for hESC-CMs has been commonly reported. Researchers mentioned that a better way for visualization of the transplanted stem cells was required in order to help direct stem cell delivery. They also added that the materials used for labeling the cells had to show maximum fluorescence and yet not confirming the viability of the cells. Dr. Boddington said "We found the ICG-labeling technique advantageous because it is cost effective, straightforward and rapid," she added "Its most noticeable advantage is that it can be used with iron oxide-based nano-particles for use with MRIs, as it increases single cell sensitivity. This is important because of the unpredictable migrational dynamics of the cells." Moreover, the study said that despite PET techniques are showing more single cell sensitivity than MRI, PET is associated with radiation exposure and therefore more risks. Yet, optical imaging applying the MRI is rapidly, less expensive, of easier performance, and noninvasive procedure. Dr. Boddington added that another advantage of the ICG is that it is quickly excreted and this indicates safe elimination. Dr. Boddington concluded "Our data suggests that hESCs labeled with ICG may be useful in assessing delivery routes to improve the engraftment of transplanted hESC-CMs or other stem cell progenitors," While Dr. Dwaine Emerich, section editor for Cell Transplantation, confirmed that the study was significant. He said "These studies are an important step forward in the quest for techniques to label and visualize stem cells in vivo,"  he added "The ICG-labeling technique described by Boddington and colleagues provides several advantages including its straight forward simplicity, reliability, and the fact that the technique can be easily combined with other developing imaging ... Read more

CT aids in detection of heart diseases, study…

According to a recent study, the high-speed advanced imaging CT technology can aid in diagnosis and prediction of patients at risk for heart attack and thus reduce death cases caused by it. The study was carried out at the University of Ottawa Heart ... Read more

FDA Approves IDE to Evaluate AMPLATZER Cardiac Plug…

The U.S. Food and Drug Administration (FDA) Approved Investigational Device Exemption (IDE), developed by AGA Medical Holdings. Mainly, IDE is developed for evaluating the safety and efficacy of its AMPLATZER® Cardiac Plug, or ACP, to close the left atrial appendage. President and Chief Executive Officer of AGA Medical, John Barr said, “Approval of this study will now allow us to further evaluate our approach to reducing strokes in patients with atrial fibrillation by using our AMPLATZER Cardiac Plug to permanently seal the appendage, hopefully sparing patients from spending the rest of their lives on anticoagulants.” However, the study's trial design will include a feasibility phase to be followed by a pivotal phase. Then, the results of the feasibility phase will serve to validate safety conclusions demonstrated through pre-clinical ... Read more

A New Breakthrough in Surgical Electronics Technology…

University of Illinois researchers, in collaboration with the University of Pennsylvania School of Medicine and Northwestern University developed a flexible sensor array that can wrap around the heart to map large areas of tissue at once. This ... Read more

Toshiba presents its modified CT scanning systems…

There is an increasing need on reducing radiation exposure while improving the quality of produced images. Cardiac imaging is one of the procedures requiring attention, since the procedure depends on high doses and longer examination times.To meet that need, Toshiba announced that it had made software improvements on its Aquilion ONE and Aquilion Premium CT systems. These improvements aim to reduce radiation exposure, while enhances efficiency, and offers high-leveled and qualified images. The new ONE Beat Prospective Reconstruction decreases radiation doses by nearly 21% and even reduces the time of the procedure. The Real Time Beat Control is calculating the running real time average heart rate to accurately estimate the next heart beat for a more precise scans. This will be useful especially for patients suffering from arrhythmia or unstable heart rates. The SUREStart feature can organize contrast uptake resulting in more accurate images. Hence, it enhances image quality and reduces the contrast dose. Toshiba’s Aquilion ONE dynamic volume CT has 320-detector rows and is capable of scanning a whole organ in a single pass. Moreover, it produces 4D videos previewing an organ's details including structure, movement, and blood flow. The Aquilion Premium is developed to ensure clinical accuracy and safety. Toshiba has supplied it with 160-detector rows system to produce images of up to 8 cm of anatomy in a single gantry rotation and can be used on patients up to 660 ... Read more

A technique applied during ECG-triggered CTA lowers …

According to a new study, the reduction or even stop of "padding" while ECG-triggered coronary CT angiography (CTA) is carried out will results in significant decrease in radiation dose without reducing image quality. The study was ... Read more

FDA says Medtronic's pacemakers are safe with MRI…

Medtronic, Inc. today mentioned that the United States Food and Drug Administration (FDA) has approved, with conditions, the use of Revo MRI SureScan pacing system. The system was developed to be safe with MRI scans. It is not recommended in the United States that patients with pacemakers perform MRI. Yet, Revo MRI would be the first FDA-approved pacing device developed to be compatible with the use of MRI. Pat Mackin, president of the Cardiac Rhythm Disease Management business and senior vice president at Medtronic, said “MRI is critical in the diagnosis of many serious conditions; however, patients with current pacemakers most often do not have access to this vital technology,” he added “The result of today’s panel brings Medtronic one step closer to helping address an important unmet patient need. We look forward to working with the FDA during the regulatory process so that we may provide certain pacemaker patients with access to MRI scans.” It is a fact that the number of MRI scans carried out is increasing every year. In the same time, the number of people having pacemakers is increasing as well. In 2007, there were nearly 30 million MRI scans performed in the United States and that number is still growing. Estimations say that more than 200,000 patients per year in the United States are not having an MRI scan because they use a pacemaker as there are risks of having such scans. Among these risks is interference with pacemaker operation, occurrence of damage to system components, increase in the temperature of the lead tips and even unwanted cardiac stimulation. Yet, MRI scans permit physicians to have diagnosis aided by viewing highly quality images of internal organs, muscles, joints, and tumors. The FDA revised safety and effectiveness data obtained from multicenter trial carried out at 42 centers around the world involving 464 patients having pacemakers. The use of Revo MRI pacing system in the MRI environment was assessed. For safety, the patients with pacemakers where checked for MRI related complications within one month after the carrying out of MRI. While effectiveness was determined by testing the equivalence between MRI group against control for atrial/ ventricular pacing capture thresholds and atrial/ ventricular sensed amplitudes in one month time after ... Read more

FDA Approves CRT-D Device for Heart Failure Treatment…

Boston Scientific developed CRT-D device to treat patients with severe heart failure. Consequently, U.S. Food and Drug Administration (FDA) approved CRT-D in order to reduce the risk of cardiac disease. The cardiac resynchronization therapy ... Read more

Men with Erectile Dysfunction Disposed to Heart Disease…

In a study published in Journal of the American Heart Association, men who are suffering from erectile dysfunction (ED) are very disposed to developing cardiovascular disease. The results revealed that men with ED and cardiovascular disease were 1.9 times more likely to die from cardiovascular disease. Wheres those who are likely to have a heart attack, are more likely to be hospitalized for heart failure. Michael Bohm, MD, lead author of the study and chairman of internal medicine at the University of Saarland in Germany, commented “Erectile dysfunction is something that regularly should be addressed in the medical history of patients. It might be a symptom of early atherosclerosis.” Thus, he suggests that men with ED going to a general practitioner, or a urologist need to be referred for a cardiology workup to determine existing cardiovascular ... Read more

Epicardial fat images aid in heart disease prediction…

According to a new study carried out at Emory University School of Medicine, cardiology professionals say that images of epicardial adipose tissue, the fat layer surrounding the heart, would offer more information about heart disease in comparison ... Read more

Agfa HealthCare Expands The Accessibility of IMPAX …

Agfa HealthCare showcased remote capabilities that expand the accessibility of its IMPAX Cardiovascular Suite throughout the hospital enterprise at the American College of Cardiology (ACC) 2010 Annual Scientific Session. IMPAX CRS Remote was mainly ... Read more

GE Healthcare's MAC 800 to help physicians at …

GE Healthcare mentioned that the company's portable ECG (electrocardiograph) device, the MAC 800, will be installed in both Vancouver and Whistler to provide support to physicians offering healthcare to athletes, trainers and visitors during the ... Read more

Philips Develop Hybrid OR Suite for Cardiac Procedures…

Philips and ACC will introduce the Hybrid OR Suite at ACC 2010. Hybrid OR Suite is a solution that combines the equipment needed to perform open and endovascular cardiac procedures. In addition, the Hybrid OR Suite, developed by Philips, will help advance how clinicians attend to patients in cardiac procedures. What is amazing about Hybrid OR Suite is that it combines the instruments of a traditional operating room with the X-ray, and ultrasound imaging systems and radiation shields of a cath lab.  "Using live 3D TEE ultrasound, we can view the anatomy without incisions or surgery," said Roberto Lang, M.D., director of Noninvasive Cardiac Imaging Labs. "It provides 3D images unlike those from other technology, to help clinicians place therapeutic devices." Hybrid OR Suite is designed using an advanced 3D architectural planning tool that provides customers with a visual rendering of possible room ... Read more

Page 14 of 15

These signals are relayed buying clomid online safe which then is by a number of such as medial preoptic and paraventricular nulcei.
javporn.cc